Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. Sekeres MA, et al. Among authors: ma ww. Ann Hematol. 2022 Aug;101(8):1689-1701. doi: 10.1007/s00277-022-04853-4. Epub 2022 Apr 30. Ann Hematol. 2022. PMID: 35488900 Clinical Trial.
Acute myeloid leukemia.
Stone RM, O'Donnell MR, Sekeres MA. Stone RM, et al. Among authors: sekeres ma. Hematology Am Soc Hematol Educ Program. 2004:98-117. doi: 10.1182/asheducation-2004.1.98. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561679 Review.
The epidemiology of myelodysplastic syndromes.
Sekeres MA. Sekeres MA. Hematol Oncol Clin North Am. 2010 Apr;24(2):287-94. doi: 10.1016/j.hoc.2010.02.011. Hematol Oncol Clin North Am. 2010. PMID: 20359626 Review.
Combination strategies in myelodysplastic syndromes.
Ornstein MC, Sekeres MA. Ornstein MC, et al. Among authors: sekeres ma. Int J Hematol. 2012 Jan;95(1):26-33. doi: 10.1007/s12185-011-0987-4. Epub 2012 Jan 6. Int J Hematol. 2012. PMID: 22218883 Review.
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Sugimoto Y, et al. Among authors: sekeres ma. J Hematol Oncol. 2012 Mar 5;5:4. doi: 10.1186/1756-8722-5-4. J Hematol Oncol. 2012. PMID: 22390313 Free PMC article.
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Raza A, et al. Among authors: sekeres ma. J Hematol Oncol. 2012 Apr 30;5:18. doi: 10.1186/1756-8722-5-18. J Hematol Oncol. 2012. PMID: 22546242 Free PMC article. Clinical Trial.
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Sekeres MA, et al. Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22. Blood. 2012. PMID: 22915641 Free PMC article. Clinical Trial.
428 results